Oral Abstract Session 01 - Global HIV Vaccine Enterprise
Oral Abstract Session 01 - Global HIV Vaccine Enterprise
Oral Abstract Session 01 - Global HIV Vaccine Enterprise
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Tuesday, 11 September<br />
Program<br />
Poster Discussion 3b: BCEC Level 3,<br />
<strong>Vaccine</strong> Concepts and Design Ballroom West<br />
Chair: Eric Sandström<br />
18:30 – 18:37 Targeting <strong>HIV</strong>-1 Envelope Glycoprotein Trimers to B Cells Using APRIL P12.11<br />
Improves Antibody Responses<br />
M Melchers, I Bontjer, T Tong, N Chung, P Klasse, D Eggink, M Gentile,<br />
A Cerutti, D Montefiori, W Olson, B Berkhout, J Binley, J Moore, R Sanders<br />
18:37 – 18:44 Extensive Glycoform Heterogeneity in the gp120 Envelope Proteins P12.07<br />
Used in the RV144 Trial<br />
B Yu, JF Morales, SM O’Rourke, GP Tatsuno, PW Berman<br />
18:44 – 18:51 Native Envelope-based Immunogens Derived from Critical Timepoints P12.56<br />
in the Development of Breadth Elicit Rapid Neutralizing Antibodies in Rabbits<br />
DC Malherbe, AJ Hessell, ND Sather, B Guo, S Pandey, F Pissani, H Robins,<br />
S Kalams, L Stamatatos, NL Haigwood<br />
18:51 – 18:58 A Minimal T-cell Immunogen Designed to Cover <strong>HIV</strong>-1 Specificities P12.16<br />
Associated with Control Is Immunogenic in Mice and Breaks<br />
CTL Immunodominance<br />
B Mothe, A Llano, M Rosati, S Perez-Alvarez, V Kulkarni, B Chowdhury,<br />
C Alicea, RK Beach, NY Sardesai, GN Pavlakis, BK Felber, C Brander<br />
18:58 – 19:05 Preferential Targeting of Conserved Gag Regions After Vaccination P12.41<br />
with a Heterologous DNA Prime Modified Vaccinia Ankara Boost<br />
<strong>HIV</strong> <strong>Vaccine</strong> Regime<br />
A Bauer, L Podola, A Haule, L Sudi, C Nilsson, P Mann, M Missanga,<br />
B Kaluwa, L Maboko, C Lueer, M Mwakatima, S Aboud, M Bakari,<br />
J Currier, M Robb, S Joseph, S McCormack, E Lyamuya, B Wahren,<br />
E Sandström, G Biberfeld, M Hoelscher, A Kroidl, C Geldmacher<br />
19:05 – 19:12 CN54gp140: Product Characteristics, Preclinical and Clinical Use - P12.62 LB<br />
Recombinant Glycoprotein for <strong>HIV</strong> Immunization<br />
D Katinger, S Jeffs, F Altmann, A Cope, P McKay, N Almond, E Sandström,<br />
B Hejdeman, G Biberfeld, C Nilsson, D Hallengärd, B Wahren, T Lehner,<br />
M Singh, DJ Lewis, C Lacey, R Shattock<br />
AIDS <strong>Vaccine</strong> 2<strong>01</strong>2<br />
19<br />
PROGRAM / TUESDAY
Change language